ClinicalTrials.gg
CompletedNCT06852092Updated Feb 28, 2025

Study on Mass Balance of [14C]HSK39297 in Healthy Chinese Adult Male Subjects

A Phase 1 interventional study of Carbon-14 labeled HSK39297 in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Health services research

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2024, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Enrollment
47th of 47
7 · median 40
Started
2024
with 11 others
Phase 1
13 of 51
5 open now
Registered
30th of 51
by date
Lead sponsor
5 of 51
Haisco Pharmaceutical Group Co., Ltd.

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 47th largest by enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2024, is one of 13 in phase 1, and was the 30th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

To evaluate the absorption, metabolism and excretion in healthy Chinese male subjects after a single oral dose of [14C]HSK39297

Read the detailed description
  1. To quantitatively analyze the total radioactivity in excreta after oral administration of [14C]HHSK39297 in healthy subjects, obtain the data on human radioactivity excretion rate and determine the main excretion pathways
  2. To quantitatively analyze the total radioactivity in whole blood and plasma in healthy subjects after oral administration of [14C]HSK39297, to obtain the pharmacokinetics of total radioactivity in plasma and to investigate the distribution of total radioactivity in whole blood and plasma
  3. To obtain the radioactive metabolite profile in plasma, urine, and feces after oral administration of [14C]HSK39297 in healthy subjects, to identify the main metabolites and to determine the metabolism and elimination pathways
03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese healthy male subjects aged between 18 and 45 years old (inclusive, at the time of signing the form);
  2. Body weight ≥ 50 kg and (BMI) within the range of 19 - 26 kg/m² (inclusive);
  3. Capable of comprehending the procedures and methodologies of this study, disposed to strictly adhere to the related requirements of the protocol, and capable of signing the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Abnormal and findings in physical examination, vital signs, laboratory tests (blood routine, biochemistry, coagulation function, urine routine, stool routine + fecal occult blood, thyroid function), ophthalmic examination (slit lamp, intraocular pressure, fundus photography), 12 - lead [ corrected by Fridericia method (QTcF), 350 - 450 ms (inclusive) for men], X - ray chest film (anterior - posterior and lateral views), abdominal B - ultrasound (liver, gallbladder, pancreas, spleen), urinary system B - ultrasound (kidneys, ureters, bladder, prostate), etc.
  2. Positive for surface antigen, virus IgG antibody, antibody and antigen p24, and Treponema pallidum antibody.
  3. Use of prescription drugs, over - the - counter drugs, or health care products, including Chinese patent medicine, within 14 days before the screening period or within 5 half - lives of the drug (whichever is longer).
  4. Participated in a clinical trial and received drugs or devices within 3 months before screening.
  5. Use of any drugs that inhibit or induce the activity of liver drug - metabolizing enzymes or P - gp inhibitors within 30 days before screening.
  6. Dysphagia or any conditions that may affect drug absorption (e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy).
  7. Habitual constipation/diarrhea (feces collection required), history of malabsorption syndrome, or severe GI symptoms within 1 week before screening.
  8. History of serious diseases in cardiovascular, digestive, etc. systems or other diseases/physiological conditions interfering with trial results.
  9. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsades de pointes, ventricular tachycardia, atrioventricular block, QT prolongation syndrome, or having symptoms of QT prolongation syndrome and a family history (indicated by genetic evidence or sudden cardiac death of close relatives at a young age).
  10. History of capsular bacterial infection (e.g., Neisseria meningitidis, etc.) within 6 months before screening.
  11. History of tuberculosis infection or currently suffering from tuberculosis.
  12. Underwent major surgery within 6 months before screening or surgical incision not healed (excluding healed appendicitis and rectal prolapse surgeries).
  13. Severely allergic, allergic to trial drugs/, two or more other drugs/foods, or having special diet requirements and unable to follow a unified diet.
  14. Having hemorrhoids or perianal diseases with regular/ongoing rectal bleeding, irritable bowel syndrome, or inflammatory bowel disease.
  15. Alcoholism or regular drinking (> 14 alcohol units/week) within 6 months before screening, or positive alcohol breath test.
  16. Smoking more than 5 cigarettes per day or habitually using nicotine - containing products within 3 months before the screening period and being unable to quit during the trial.
  17. Having drug abuse or dependence, with a positive urine drug abuse screening.
  18. Habitually drinking grapefruit juice or excessive tea (more than 8 cups a day, 1 cup = 250 mL), or excessive caffeine intake (more than 3 cups of coffee a day, etc.) and being unable to quit during the trial.
  19. Long - term exposure to radiation at work, or significant radiation exposure (≥ 2 chest/abd CT or ≥ 3 other X - rays) within 1 year before the trial, or participated in a radiopharmaceutical trial within 1 year.
  20. Received a within 1 month before screening or planned to during the trial.
  21. History of fainting at the sight of needles/blood, difficult blood collection, or intolerance to venipuncture.
  22. Fertility plan during the trial and within 1 year after the last dose, or disagreed to take strict measures.
  23. Blood loss or donation ≥ 400 mL within 3 months before screening, or received a blood transfusion within 1 month.
  24. For any reason subject is considered by the investigator to be an unsuitable candidate.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    [14C]HSK39297

    Drug: Carbon-14 labeled HSK39297

Interventions

06

What researchers measure

Primary outcomes

  1. Recovery of total radioactivity in urine and fecal samples

    Mass balance recovery of total radioactivity in urine and fecal samples

    Time frame: Up to 312 hours post dose

  2. Total radioactivity in plasma PK

    PK parameters of total radioactivity in the plasma; Ratio of total radioactivity concentration in whole blood/plasma at different time points.

    Time frame: Up to 312 hours post dose.

  3. Percentage of radioactivity and identification of metabolites in plasma, urine and fecal samples

    Percentage of prototype drugs and its metabolites in plasma, urine and fecal samples. Identification of the major metabolites

    Time frame: Up to 312 hours post dose.

Secondary outcomes

  1. Number of participants with adverse events

    All subjects will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms and ophthalmological assessments

    Time frame: Up to 312 hours post dose.

07

Study locations

1 site
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Sep 2024, 0 months.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Feb 28, 2025
StartActual
Sep 9, 2024
Primary completionActual
Sep 27, 2024
CompletionActual
Dec 10, 2024
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06852092
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Sep 9, 2024
Primary completion
Sep 27, 2024
Completion
Dec 10, 2024
Last update
Feb 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carbon-14

Start the discussion